Members of Congress offloaded Medicaid stocks ahead of announced funding reductions suspiciously
In a recent turn of events, the One Big Beautiful Bill Act (OBBBA) has passed through both chambers of Congress, raising concerns about the trading activities of some lawmakers, particularly in relation to Centene Corporation.
Centene, a health insurance company that operates in the Medicaid and Affordable Care Act (ACA) sectors, has seen a significant decline following the passage of OBBBA. The bill, which cuts Medicaid funding by $1 trillion over the next decade, imposes stricter work requirements and eligibility checks, projected to remove 10 to 12 million Americans from coverage by 2034. Centene disclosed on July 2 that enrollment and cost trends would slash earnings by $2.75 per share, causing the company's stock to plummet by nearly 40%.
The timing of recent stock trades by several lawmakers in Centene has fueled concerns about possible misuse of insider knowledge to profit from congressional actions. Rep. Ro Khanna, Rep. Robert Bresnahan, and Rep. Gilbert Ray Cisneros are among those who have sold shares of Centene stock in the past month.
While the STOCK Act (Stop Trading on Congressional Knowledge Act) was passed in 2012 to address this issue, it only requires members of Congress to publicly disclose securities trades over $1,000 within 45 days of the transaction. This delayed disclosure and the lack of an outright ban on trading stocks have led to criticism and calls for tighter restrictions or outright bans on stock trading by lawmakers.
For instance, some lawmakers have proposed the TRUST Act, which suggests divestment from individual stocks or placing investments in blind trusts to avoid conflicts of interest. However, bipartisan support for stricter regulations remains limited, and these proposed reforms have not yet been broadly implemented.
Critics argue that members of Congress should be banned from trading individual stocks due to their privileged access to nonpublic information about legislation. This access can potentially influence stock prices unfairly. Yet, such bans have not been enacted.
In light of these concerns, the practice of lawmakers trading stocks in companies affected by legislation they work on continues to be debated and viewed as ethically problematic by many. As the OBBBA's impact unfolds, the spotlight on this issue is expected to remain.
| Aspect | Current Regulation | Criticism / Limitations | |--------|--------------------|------------------------| | Disclosure | STOCK Act requires public disclosure of trades over $1,000 within 45 days | Delayed disclosure may reduce effectiveness; exact amounts can be ranges | | Trading Ban | No outright ban on trading stocks by members | Potential for insider trading and conflicts of interest remain | | Proposed Reforms | TRUST Act and calls for blind trusts or divestment | Not yet broadly implemented; political resistance exists |
The recent passing of the One Big Beautiful Bill Act (OBBBA) has sparked debates about the practice of lawmakers trading stocks, particularly in companies like Centene that are affected by the legislation they work on. Critics argue that the STOCK Act's delayed disclosure of securities trades and the lack of an outright ban on trading stocks can lead to potential insider trading and conflicts of interest. Proposed reforms such as the TRUST Act, which suggests divestment from individual stocks or placement in blind trusts, have not been broadly implemented due to political resistance.
